What’s new with DiaSorin Molecular.

Available here is a selection of our latest news about DiaSorin Molecular.
Published on 20 Sep 2021

DiaSorin Molecular CE Marks their new Simplexa™ COVID-19 & Flu A/B Direct Assay for Detection and Differentiation of SARS-CoV-2 and Influenza in One Test.

Cypress, Calif. (September 20, 2021) – DiaSorin Molecular LLC announced today that it has CE marked its Simplexa™ COVID-19 & Flu A/B Direct kit. The multiplex test allows for the in vitro qualitative detection and differentiation of nucleic acid from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A virus and influenza B virus from the same patient sample in one reaction well. The assay is designed for use on the LIAISON® MDX and is run directly from nasopharyngeal swabs (NPS) without the need for off board extraction. The kit will also be submitted to the FDA for 510(k) review.

DiaSorin Molecular
Published on 14 Jul 2021

DiaSorin Announces Completion of the Acquisition of Luminex Corporation

Saluggia, July 14, 2021 – DiaSorin S.p.A. (“DiaSorin”; FTSE MIB: DIA) announces it has completed the acquisition of Luminex Corporation (“Luminex”; NASDAQ: LMNX) for a price of USD 37.00 per share that corresponds to a total equity value of approximately USD 1.8 billion.

DiaSorin Molecular
Published on 21 May 2021

DiaSorin Molecular Releases an Assay for Rapid Identification of Mutations Associated with Circulating Variants of SARS-CoV-2, including the India B.1.617

Cypress, Calif. (May 21, 2021) – DiaSorin Molecular LLC announced today that it has released the Simplexa™ SARS-CoV-2 Variants Direct assay (RUO) to enable detection and discrimination of four SARS-CoV-2 mutations associated with circulating virus variants without requiring upfront RNA extraction. The assay helps to streamline and speed-up the pre-selection process of positive samples that need further sequencing, maximizing the effectiveness of monitoring programs for the spread of concerning variants.

DiaSorin Molecular
Published on 13 Jan 2021

DiaSorin Molecular Receives Additional BARDA Funding in Support of Submitting the Simplexa™ COVID-19 Direct and the Simplexa™ COVID-19 & Flu A/B Direct kits for FDA 510(k) Clearance

Cypress, California (USA) – January 13, 2021 – DiaSorin Molecular LLC, a subsidiary of DiaSorin S.p.A. (FTSE MIB:DIA), announced today that it has received additional federal funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, for the validation and submission of the Simplexa COVID-19 Direct kit and the Simplexa COVID-19 & Flu A/B Direct kit for FDA 510(k) clearance. The company initially received BARDA funding in March 2020 to test, validate, and submit the Simplexa COVID-19 Direct kit for FDA Emergency Use Authorization (EUA).

DiaSorin Molecular